13 research outputs found
Clinical improvement in Job syndrome following administration of co-trimoxazole, omalizumab and inhaled tobramycin
Established treatment regimens for the autosomal dominant hyperimmunoglobulin E syndrome, denominated Job syndrome, are lacking. Thus, Job syndrome still exerts a dramatic impact on patients’ quality of life. Our aim was to present safety and effectiveness of a regimen including co-trimoxazole, omalizumab and inhaled tobramycin in Job syndrome. A 26-year-old woman diagnosed with Job syndrome since infancy through sequencing revealing G342D mutation in STAT3 gene was initiated in the above mentioned treatment regimen; she was followed for 6 months, and to date, none recurrent pulmonary or skin infection was noticed. Furthermore, a considerable improvement in skin lesions was observed. A combination of anti-IgE and longitudinal use of inhaled antibiotics seems well-founded in Job syndrome
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model
IntroductionPost-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD).MethodsIn this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1.ResultsTwo hundred thirty-two (n = 232) patients were analyzed. FVC% predicted was ≥80, between 60 and 79 and <60 in 74.2% (n = 172), 21.1% (n = 49), and 4.7% (n = 11) of the cohort, respectively. DLCO% predicted was ≥80, between 60 and 79 and <60 in 69.4% (n = 161), 15.5% (n = 36), and 15.1% (n = 35), respectively. Extent of ground glass opacities was ≥30% in 4.3% of patients (n = 10), between 5 and 29% in 48.7% of patients (n = 113) and <5% in 47.0% of patients (n = 109). The extent of reticulation was ≥30%, 5–29% and <5% in 1.3% (n = 3), 24.1% (n = 56), and 74.6% (n = 173) of the cohort, respectively. Patients (n = 13, 5.6%) with fibrotic lung disease and persistent functional impairment at the 6-month follow-up received antifibrotics and presented with an absolute change of +10.3 (p = 0.01) and +14.6 (p = 0.01) in FVC% predicted at 3 and 6 months after the initiation of antifibrotic.ConclusionPost-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are “immature.” Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches
Pulmonary embolism and abdominal pain in a young patient: A case report of a rare clinical entity
A 20-year-old man with reduced mobility, from a car accident, presented to
the Emergency Department of our hospital due to progressive dyspnea and
heart palpitations the lasted three days. A bedside cardiac ultrasound and
a Computed Tomography Pulmonary Angiogram (CTPA) were immediately
performed, revealing strain of the right ventricle and pulmonary embolism (PE).
The patient subsequently complained about abdominal pain and a Computed
Tomography of the Abdominal Aorta (CTAO) revealed arterial embolism in the
renal and splenic circulations, along with the right common femoral artery.
Phlebography of inferior limbs exhibited deep vein thrombosis in the left
popliteal vein. A percutaneous suction thrombectomy had been performed
successfully.
The patient underwent a transesophageal echocardiography with agitated
saline test that revealed a patent foramen ovale (PFO), a diagnosis which
explained the paradoxical embolism in both arterial and venous circulations.
Paradoxical embolism is quite uncommon and should not be ignored in cases
with indications of arterial embolism after PE